WiseGuyReports.Com Publish a New Market Research Report On –“ Alzheimer’s Disease Therapeutics and Diagnostics Industry – Treatment Analysis,Research,Review to 2023”.

New York, NY -- (SBWire) -- 07/31/2018 --Alzheimer's disease (AD) is the most common reason of progressive dementia in the elderly population. There has been an exponential rise in the number of cases of Alzheimer's disease worldwide emphasizing the necessity for developing an effective treatment. According to Alzheimer's Association, in 2016, an estimated 5.4 million Americans of all ages have Alzheimer's disease. One in nine people aged 65 and above has Alzheimer's disease. By 2050, the number of people aged 65 and above affected with Alzheimer's disease is expected to nearly triple, from 5.2 million to an expected 13.8 million, excluding the development of medical advances to avert or cure the disease. The mortality rates due to Alzheimer's disease are quite high. Between 2000 and 2013, deaths due to heart disease, stroke and prostate cancer decreased 14%, 23% and 11%, respectively, while deaths from AD increased 71% in the U.S. Similarly, According to Alzheimer's disease International in 2015, there are an estimated 46.8 million people worldwide living with dementia and is further expected to grow in future. Thus, there is an increasing in the demand for Alzheimer's therapeutics and diagnostics worldwide.

Population aging across the globe is a major factor driving the market for Alzheimer's therapeutics and diagnostics. Rising life expectancy is contributing to quick increases in number of aged population, and is associated with increased prevalence of chronic diseases like dementia. Therapies for AD offer temporary and uncertain improvements in the well-being of individuals, and none of the approved drugs can modify the course of the disease advancement. Thus, the magnitude of the affected population and lack of suitable and effective treatment offers an incredible opportunity for drug manufacturers. However, identification of the primary reasons and mechanisms involved in AD are is limited. Drug manufacturers have been unable to validate significant clinical benefits of treatment for a numerous of new compounds due to strict regulations. One of the significant trend observed in this market is collaboration of the existing players. Precisely, diagnostic technology companies are carefully trying to bring about effective biomarker technologies to support and improve the drug development process for potential drug candidates which is further expected to propel the demand.

Get a Sample Report @ https://www.wiseguyreports.com/sample-request/3304674-global-north-america-europe-asia-pacific-south-america

For more information or any query mail at sales@wiseguyreports.com

Scope of the Report:
This report focuses on the Alzheimer's Disease Therapeutics and Diagnostics in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

The worldwide market for Alzheimer's Disease Therapeutics and Diagnostics is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers
Namenda
Aricept
Exelon
Solanezumab
Gantenerumab
Verubecestat
Pfizer
Eisai
Actavis
Lundbeck
Daiichi Sankyo
Novartis
TauRx

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Biomarkers
Cholinesterase inhibitors
NMDA receptor antagonists
Brain imaging
Blood tests

Market Segment by Applications, can be divided into
Drugs Market
Diagnostics Market

Ask Query @ https://www.wiseguyreports.com/enquiry/3304674-global-north-america-europe-asia-pacific-south-america

Table Of Contents – Major Key Points

1 Market Overview
1.1 Alzheimer's Disease Therapeutics and Diagnostics Introduction
1.2 Market Analysis by Type
1.2.1 Biomarkers
1.2.2 Cholinesterase inhibitors
1.2.3 NMDA receptor antagonists
1.2.4 Brain imaging
1.2.5 Blood tests
1.3 Market Analysis by Applications
1.3.1 Drugs Market
1.3.2 Diagnostics Market
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force

2 Manufacturers Profiles
2.1 Namenda
2.1.1 Business Overview
2.1.1.1 Namenda Description
2.1.1.2 Namenda Headquarter, Main Business and Finance Overview
2.1.2 Namenda Alzheimer's Disease Therapeutics and Diagnostics Product Introduction
2.1.2.1 Alzheimer's Disease Therapeutics and Diagnostics Production Bases, Sales Regions and Major Competitors
2.1.2.2 Alzheimer's Disease Therapeutics and Diagnostics Product Information
2.1.3 Namenda Alzheimer's Disease Therapeutics and Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.1.3.1 Namenda Alzheimer's Disease Therapeutics and Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.1.3.2 Global Namenda Alzheimer's Disease Therapeutics and Diagnostics Market Share in 2017
2.2 Aricept
2.2.1 Business Overview
2.2.1.1 Aricept Description
2.2.1.2 Aricept Headquarter, Main Business and Finance Overview
2.2.2 Aricept Alzheimer's Disease Therapeutics and Diagnostics Product Introduction
2.2.2.1 Alzheimer's Disease Therapeutics and Diagnostics Production Bases, Sales Regions and Major Competitors
2.2.2.2 Alzheimer's Disease Therapeutics and Diagnostics Product Information
2.2.3 Aricept Alzheimer's Disease Therapeutics and Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2.3.1 Aricept Alzheimer's Disease Therapeutics and Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2.3.2 Global Aricept Alzheimer's Disease Therapeutics and Diagnostics Market Share in 2017
2.3 Exelon
2.3.1 Business Overview
2.3.1.1 Exelon Description
2.3.1.2 Exelon Headquarter, Main Business and Finance Overview
2.3.2 Exelon Alzheimer's Disease Therapeutics and Diagnostics Product Introduction
2.3.2.1 Alzheimer's Disease Therapeutics and Diagnostics Production Bases, Sales Regions and Major Competitors
2.3.2.2 Alzheimer's Disease Therapeutics and Diagnostics Product Information
2.3.3 Exelon Alzheimer's Disease Therapeutics and Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3.3.1 Exelon Alzheimer's Disease Therapeutics and Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3.3.2 Global Exelon Alzheimer's Disease Therapeutics and Diagnostics Market Share in 2017
2.4 Solanezumab
2.4.1 Business Overview
2.4.1.1 Solanezumab Description
2.4.1.2 Solanezumab Headquarter, Main Business and Finance Overview
2.4.2 Solanezumab Alzheimer's Disease Therapeutics and Diagnostics Product Introduction
2.4.2.1 Alzheimer's Disease Therapeutics and Diagnostics Production Bases, Sales Regions and Major Competitors
2.4.2.2 Alzheimer's Disease Therapeutics and Diagnostics Product Information
2.4.3 Solanezumab Alzheimer's Disease Therapeutics and Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4.3.1 Solanezumab Alzheimer's Disease Therapeutics and Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4.3.2 Global Solanezumab Alzheimer's Disease Therapeutics and Diagnostics Market Share in 2017

Continued……

For more information or any query mail at sales@wiseguyreports.com

About Wise Guy Reports
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.